Fig 2: LAGE3 co-expressed genes and functional enrichment analysis. (A) Heatmaps showing the top 30 genes positively and negatively correlated with LAGE3. (B) GO enrichment analysis (top 10 terms of each subtype) and (C) KEGG enrichment analysis based on genes co-expressed with LAGE3. (D) GSEA analyses displayed key pathways associated with LAGE3 expression.

Fig 3: Effects of eleutheroside B1 on the expression of NEAT1 and LAGE3 in the A/PR/8 (MOI=0.1)-infected A549 cells. (A) NEAT1 expression levels. (B) LAGE3 mRNA expression levels. *P<0.05. NEAT1, nuclear paraspeckle assembly transcript 1; LAGE3, L antigen family member 3.

Fig 4: Prognostic value of LAGE3 in BC patients in the METABRIC cohort. (A, B) OS and RFS between LAGE3 high and low groups. Multivariate Cox regression analysis of LAGE3 expression for (C) OS and (D) DSS in BC patients. OS, overall survival; DSS, disease-specific survival.

Fig 5: Correlation of LAGE3 expression with clinicopathological characteristics of BC patients. (A) LAGE3 expression in the different tumor sizes, lymph node metastasis, distant metastasis, and stage subgroups in the TCGA dataset. (B) LAGE3 expression in different tumor sizes, lymph node metastasis, tumor grade, and stage subgroups in METABRIC dataset. (C) LAGE3 expression level in wild-type and mutated TP53 groups. (D) PPI network of LAGE3, TP53, and their related genes. PPI, Protein–protein interaction.